Gilead Sciences (NASDAQ:GILD) Stock Unloaded Rep. Val T. Hoyle

Key Points

• Representative Val T. Hoyle sold shares of Gilead Sciences (NASDAQ:GILD) worth between $1,001 and $15,000 from her FIDELITY ROLLOVER IRA account on September 23rd, as disclosed in a filing made on October 10th.
• Gilead Sciences reported $2.01 EPS for the last quarter, exceeding analyst expectations, and has set its FY 2025 guidance at 7.950-8.250 EPS.
• The company also announced a quarterly dividend of $0.79 per share, representing an annual yield of 2.7% and a dividend payout ratio of 62.95%.

Representative Val T. Hoyle (D-Oregon) recently sold shares of Gilead Sciences, Inc. NASDAQ: GILD. In a filing disclosed on October 10th, the Representative disclosed that they had sold between $1,001 and $15,000 in Gilead Sciences stock on September 23rd. The trade occurred in the Representative's "FIDELITY ROLLOVER IRA" account.

Representative Val T. Hoyle also recently made the following trade(s):

• Sold $1,001 - $15,000 in shares of Marriott International NASDAQ: MAR on 9/23/2025.
• Sold $1,001 - $15,000 in shares of Transdigm Group NYSE: TDG on 9/23/2025.
• Sold $1,001 - $15,000 in shares of H&R Block NYSE: HRB on 9/23/2025.
• Sold $1,001 - $15,000 in shares of NIKE NYSE: NKE on 9/23/2025.
• Sold $1,001 - $15,000 in shares of Bank of New York Mellon NYSE: BK on 9/23/2025.
• Sold $1,001 - $15,000 in shares of Cisco Systems NASDAQ: CSCO on 9/23/2025.
• Sold $1,001 - $15,000 in shares of Capital One Financial NYSE: COF on 9/23/2025.
• Sold $1,001 - $15,000 in shares of Pentair NYSE: PNR on 9/23/2025.
• Sold $1,001 - $15,000 in shares of Heico NYSE: HEI.A on 9/23/2025.
• Sold $1,001 - $15,000 in shares of Target NYSE: TGT on 9/23/2025.

Gilead Sciences Stock Up 0.4%

GILD opened at $117.18 on Friday. The stock has a fifty day moving average of $114.65 and a 200-day moving average of $110.25. The company has a market capitalization of $145.40 billion, a P/E ratio of 23.34, a P/E/G ratio of 0.79 and a beta of 0.34. Gilead Sciences, Inc. has a fifty-two week low of $84.17 and a fifty-two week high of $121.83. The company has a debt-to-equity ratio of 1.13, a quick ratio of 1.15 and a current ratio of 1.32.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 EPS for the quarter, topping analysts' consensus estimates of $1.96 by $0.05. The business had revenue of $7.08 billion for the quarter, compared to analyst estimates of $6.95 billion. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. Gilead Sciences's revenue for the quarter was up 1.4% compared to the same quarter last year. During the same period last year, the firm earned $2.01 earnings per share. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. On average, equities analysts expect that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, September 29th. Shareholders of record on Monday, September 15th were given a dividend of $0.79 per share. The ex-dividend date was Monday, September 15th. This represents a $3.16 annualized dividend and a yield of 2.7%. Gilead Sciences's dividend payout ratio (DPR) is presently 62.95%.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Rothschild Investment LLC grew its holdings in shares of Gilead Sciences by 1.9% during the 2nd quarter. Rothschild Investment LLC now owns 4,539 shares of the biopharmaceutical company's stock valued at $503,000 after purchasing an additional 84 shares during the last quarter. Ignite Planners LLC boosted its position in Gilead Sciences by 1.1% in the third quarter. Ignite Planners LLC now owns 7,932 shares of the biopharmaceutical company's stock valued at $880,000 after buying an additional 86 shares in the last quarter. Archer Investment Corp grew its stake in shares of Gilead Sciences by 1.2% during the second quarter. Archer Investment Corp now owns 7,277 shares of the biopharmaceutical company's stock worth $807,000 after buying an additional 87 shares during the last quarter. Binnacle Investments Inc increased its holdings in shares of Gilead Sciences by 14.3% during the second quarter. Binnacle Investments Inc now owns 702 shares of the biopharmaceutical company's stock worth $78,000 after buying an additional 88 shares in the last quarter. Finally, EPG Wealth Management LLC lifted its stake in shares of Gilead Sciences by 2.0% in the 2nd quarter. EPG Wealth Management LLC now owns 4,627 shares of the biopharmaceutical company's stock valued at $513,000 after acquiring an additional 89 shares during the last quarter. Institutional investors and hedge funds own 83.67% of the company's stock.

Insider Buying and Selling

In other news, CFO Andrew D. Dickinson sold 2,500 shares of Gilead Sciences stock in a transaction dated Monday, September 15th. The stock was sold at an average price of $113.57, for a total transaction of $283,925.00. Following the sale, the chief financial officer directly owned 159,555 shares of the company's stock, valued at approximately $18,120,661.35. This trade represents a 1.54% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Daniel Patrick O'day sold 10,000 shares of the company's stock in a transaction that occurred on Monday, September 29th. The shares were sold at an average price of $111.66, for a total value of $1,116,600.00. Following the completion of the transaction, the chief executive officer directly owned 591,203 shares of the company's stock, valued at $66,013,726.98. This represents a 1.66% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 82,000 shares of company stock worth $9,402,130 in the last 90 days. Insiders own 0.27% of the company's stock.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on GILD. Royal Bank Of Canada boosted their price target on Gilead Sciences from $98.00 to $100.00 and gave the company a "sector perform" rating in a research note on Wednesday. Daiwa America upgraded Gilead Sciences from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, August 19th. Truist Financial upgraded Gilead Sciences from a "hold" rating to a "buy" rating and raised their price target for the stock from $108.00 to $127.00 in a research report on Friday, August 8th. Citigroup boosted their price target on Gilead Sciences from $125.00 to $135.00 and gave the company a "buy" rating in a research note on Wednesday. Finally, JPMorgan Chase & Co. upped their price objective on shares of Gilead Sciences from $135.00 to $145.00 and gave the stock an "overweight" rating in a research report on Tuesday, September 16th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and six have assigned a Hold rating to the company. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $118.08.

About Representative Hoyle

Val Hoyle (Democratic Party) is a member of the U.S. House, representing Oregon's 4th Congressional District. She assumed office on January 3, 2023. Her current term ends on January 3, 2027. Hoyle (Democratic Party) is running for re-election to the U.S. House to represent Oregon's 4th Congressional District. She declared candidacy for the 2026 election. Val Hoyle was born in California and lives in Springfield, Oregon. Hoyle graduated from Merrimack High School. She earned a B.A. in political science from Emmanuel College in 1992. Her career experience includes working as a director at United Way of Lane County, a policy fellow at Wayne Morse Center for Law and Politics, and a commissioner at the Oregon Bureau of Labor and Industries. Hoyle has also worked in domestic and international sales, as well as manufacturing distribution.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.